Profile image
Story Views

Last Hour:
Last 24 Hours:

Postmenopausal Osteoporosis Drugs Market 2016 Trend, Analysis and Overview

Monday, February 20, 2017 23:13
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.
Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.

Publisher’s analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.

For more information about this report: .

Covered in this report 
The report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis.

The market is divided into the following segments based on geography: 
- Americas

Publisher’s report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
- Eli Lilly
- Amgen
- Merck
- Novartis


Request Sample Copy at .    


Other prominent vendors 
- Allergan
- Amgen Astellas Biopharm 
- Deltanoid Pharmaceuticals
- Noven
- Novo Nordisk
- Osteologix
- Pfizer
- PhytoHealth
- Radius Health
- Tarsa Therapeutics
- Uni-Bio Science Group
- Upsher-Smith Laboratories
- Watson Pharmaceuticals
- Zosano Pharma

Market driver 
- Growing prevalence of postmenopausal osteoporosis 
- For a full, detailed list, view our report 

Market challenge 
- Low diagnosis rate
- For a full, detailed list, view our report 

Market trend 
- Emergence of novel agents
- For a full, detailed list, view our report 

Inquire for Report at .     

Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.